Mark Vaeck, PhDChief Executive Officer; Complix NV (Belgium)Mark Vaeck co-founded Complix in 2008 and has been a member of the Board since its inception. In May 2010 he helped raising the Series A financing round of Complix and was elected CEO shortly thereafter. From June 2006 until April 2010 Mark has been the founding CEO of ActoGeniX, a biopharmaceutical company based in Ghent (Belgium) developing novel protein therapeutics formulated for oral delivery. As CEO of ActoGeniX he raised over 35 million Euro in two rounds of equity financing. In June 2001 Mark co-founded Ablynx NV (Belgium), a biopharmaceutical company developing therapeutic antibody fragments (“Nanobodies”), and served as its CEO until May 2006. As CEO of Ablynx he raised 30 million Euro in equity financing and concluded several corporate deals with major pharmaceutical companies. Prior to joining Ablynx he was Chief Operating Officer of Ceres Inc., a NASDAQ listed company based in California and focused on the development of innovative technologies for biofuel production. Between 1993 and 1998 he served as Director Business Development and thereafter as CEO of Keygene N.V., a biotechnology company in The Netherlands. Between 1983 and 1993 Mark held several management positions in the biotechnology and pharma industry, including Director Business Development at EuroCetus (Chiron Corp.), Manager Licensing at UCB Pharma, and Manager Business Development at Plant Genetic Systems. During the past decade he has also been serving as chairman of the BioWin jury, which reviews new life sciences projects funded by the regional government in Wallonia. Mark is currently also chairman of the Board of myNEO Therapeutics, a leading cancer drug development company, pioneering a novel class of immunotherapies.Dr. Mark Vaeck received his PhD in Immunology in 1982 from the University of Brussels